Our recent published studies demonstrate that EGFR-targeted inhibitors induce an interferon (IFN) response program that varies markedly between distinct EGFR mutant lung cancer cell lines and positively associates with the duration of therapeutic response in EGFR-mutant lung cancer patients7. The gene discussed is EGFR; the disease is lung cancer.